Sugi Predict

Sugi Predict / Targets / CCNA1

CCNA1

Cyclin-A1 · P78396 · CCNA1 on Sugi Atlas →

92,347 patent compounds predicted against CCNA1, 53,499 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21169 SCHEMBL21169 0.55 19/20
SCHEMBL20693 SCHEMBL20693 0.53 19/20
SCHEMBL19015 SCHEMBL19015 0.51 19/20
SCHEMBL214000 SCHEMBL214000 0.61 18/20
SCHEMBL31357 SCHEMBL31357 0.50 18/20
SCHEMBL31358 SCHEMBL31358 0.50 18/20
SCHEMBL214742 SCHEMBL214742 0.52 17/20
Methylguanine Methylguanine (SCHEMBL34851) 0.51 16/20
Methylguanine Methylguanine (SCHEMBL231097) 0.69 14/20
Purvalanol B Purvalanol B (SCHEMBL27951) 1.00 13/20
Tetrabuthylammonium Tetrabuthylammonium (SCHEMBL200612) 0.58 12/20
SCHEMBL21483 SCHEMBL21483 0.56 11/20
SCHEMBL20332 SCHEMBL20332 0.52 11/20
SCHEMBL29182 SCHEMBL29182 0.52 11/20
SCHEMBL135690 SCHEMBL135690 0.51 11/20
Thioguanine Thioguanine (SCHEMBL183648) 0.51 11/20
SCHEMBL20155 SCHEMBL20155 0.51 11/20
SCHEMBL22364 SCHEMBL22364 0.50 11/20
2,6-Diaminopurine 2,6-Diaminopurine (SCHEMBL24053) 0.54 10/20
SCHEMBL20761 SCHEMBL20761 0.52 10/20

Clinical trials — most relevant to CCNA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations PHASE2UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies PHASE1RECRUITING
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics PHASE1RECRUITING
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Prevalence of Dysplasia of the Gastric Cardia nanCOMPLETED
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNA1 binder may also engage these)

ProteinNameSimilarity
Q92161 — 0.998 Q92161 →
Q61456 — 0.995 Q61456 →
Q6AY13 — 0.993 Q6AY13 →
Q9C968 — 0.993 Q9C968 →
P04962 — 0.992 P04962 →
P37881 — 0.989 P37881 →
CCNA2 Cyclin-A2 0.989 landscape →
O14332 — 0.988 O14332 →
P51943 — 0.988 P51943 →
P46278 — 0.988 P46278 →
Q0JNK6 — 0.988 Q0JNK6 →
Q7XSJ6 — 0.988 Q7XSJ6 →
Q01J96 — 0.988 Q01J96 →
P30274 — 0.988 P30274 →
Q39068 — 0.987 Q39068 →
P47827 — 0.987 P47827 →
Q38819 — 0.986 Q38819 →
P18063 — 0.985 P18063 →
Q0JPA4 — 0.985 Q0JPA4 →
Q3ECW2 — 0.985 Q3ECW2 →
P18606 — 0.985 P18606 →
Q9SFW6 — 0.984 Q9SFW6 →
Q39070 — 0.984 Q39070 →
E1C2V1 — 0.984 E1C2V1 →
USP19 Ubiquitin carboxyl-terminal hydrolase 19 0.984 landscape →
A2YH60 — 0.982 A2YH60 →
Q0D9C7 — 0.982 Q0D9C7 →
D6RBQ6 — 0.982 D6RBQ6 →
Q6IVY4 — 0.981 Q6IVY4 →
Q0WX57 — 0.981 Q0WX57 →